EFFECT OF TRANEXAMIC ACID ON PLATELET REQUIREMENTS IN THROMBOCYTOPENIC PATIENTS

我们建议研究口服抗纤溶治疗的益处， 氨甲环酸在血小板计数低于 超过20,000个/微升。 这些患者有很大的风险 出血，并可能遭受鼻衄，口腔，胃肠道，胃肠道或中枢神经系统出血。 目前，这些患者接受血小板输注治疗， 以降低出血风险。 然而，这样的输血并非没有 发病率：肝炎、同种免疫、过敏性和发热性输血 反应和容量超负荷都可能由血小板输注引起。 向门诊病人提供血小板在后勤上也很困难， 美国许多地区的血小板输注是不可用的。 此外，这样的输血是昂贵的，并且需要大容量输血的患者需要大量输血。 血小板的数量可能会对采购计划提供 他们 抗纤溶治疗已被证明对 一些与出血相关的临床情况。 我们希望建立 血小板减少症患者将受益于抗纤溶治疗 减少出血和输血的次数。

We propose to study the benefit of oral antifibrinolytic therapy with tranexamic acid in thrombocytopenic patients with platelet counts of less than 20,000/microliter. These patients are at significant risk for bleeding, and may suffer epistaxis, oral, GI, GU or CNS hemorrhage. Currently, these patients are treated with platelet transfusiions in order to minimize this bleeding risk. However, such transfusions are not without morbidity: hepatitis, alloimmunization, allergic and febrile transfusion reactions, and volume overload may all result from platelet transfusions. It is also logistically difficult to give platelets to outpatients, and in many areas of the U.S. platelets for transfusion are not available. Moreover, such transfusions are expensive, and patients requiring large numbers of platelets may tax the ability of procurement programs to provide them. Antifibrinolytic therapy has been shwon to be of proven efficacy in some clinical situations associated with bleeding. We hope to establish that thrombocytopenic patients will benefit from antifibrinolytic therapy by having fewer bleeding episodes and requiring fewer transfusions.